BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9728613)

  • 1. CD31 immunoreactivity in carcinomas and mesotheliomas.
    De Young BR; Frierson HF; Ly MN; Smith D; Swanson PE
    Am J Clin Pathol; 1998 Sep; 110(3):374-7. PubMed ID: 9728613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Surfactant protein and thyroid transcription factor 1 in pleuro-pulmonary neoplasia. Immunohistochemical study].
    Dessy E; Falleni M; Del Curto B; Braidotti P; Pietra GG
    Pathologica; 2000 Dec; 92(6):496-502. PubMed ID: 11234300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type.
    Comin CE; Dini S; Novelli L; Santi R; Asirelli G; Messerini L
    Am J Surg Pathol; 2006 Apr; 30(4):463-9. PubMed ID: 16625092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal lamina reduplication in malignant epithelioid pleural mesothelioma.
    Di Muzio M; Spoletini L; Strizzi L; Procopio A; Tassi G; Casalini A; Modesti A
    Ultrastruct Pathol; 1998; 22(6):467-75. PubMed ID: 9891926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura.
    Soini Y; Kinnula V; Kahlos K; Pääkkö P
    J Clin Pathol; 2006 Mar; 59(3):250-4. PubMed ID: 16505274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Podoplanin as a marker for mesothelioma.
    Kimura N; Kimura I
    Pathol Int; 2005 Feb; 55(2):83-6. PubMed ID: 15693854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
    Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
    Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].
    Jaouen A; Thivolet-Bejui F; Chalabreysse L; Piaton E; Traverse-Glehen A; Isaac S; Decaussin-Petrucci M; Depaepe L; Fontaine J; Remy I; Maury JM; Brevet M
    Ann Pathol; 2016 Apr; 36(2):111-9. PubMed ID: 26995100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleural mesotheliomas have an integrin profile distinct from visceral carcinomas.
    Koukoulis GK; Shen J; Monson R; Warren WH; Virtanen I; Gould VE
    Hum Pathol; 1997 Jan; 28(1):84-90. PubMed ID: 9013837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of pulmonary and pleural neoplasms with monoclonal antibodies B72.3 and CSLEX-1.
    Koukoulis GK; Radosevich JA; Warren WH; Rosen ST; Gould VE
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1990; 58(6):427-33. PubMed ID: 1972825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melan A (A103) is not a marker of mesothelioma.
    Ordóñez NG; Shen SS; Zenali M; Deavers MT
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):181-4. PubMed ID: 22820661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature.
    Butnor KJ; Burchette JL; Sporn TA; Hammar SP; Roggli VL
    Arch Pathol Lab Med; 2004 May; 128(5):538-43. PubMed ID: 15086281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
    Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
    Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin.
    Hecht JL; Pinkus JL; Weinstein LJ; Pinkus GS
    Am J Clin Pathol; 2001 Oct; 116(4):483-8. PubMed ID: 11601132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms.
    Cagle PT; Truong LD; Roggli VL; Greenberg SD
    Am J Clin Pathol; 1989 Nov; 92(5):566-71. PubMed ID: 2479255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions.
    Facchetti F; Lonardi S; Gentili F; Bercich L; Falchetti M; Tardanico R; Baronchelli C; Lucini L; Santin A; Murer B
    Virchows Arch; 2007 Sep; 451(3):669-80. PubMed ID: 17609977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.